Antimicrobial resistance among Acinetobacter baumannii is increasing worldwide, often
necessitating combination therapy. The clinical utility of using minocycline with polymyxin B …

Minocycline-based combination therapy has been suggested to be a possible choice for the
treatment of infections caused by minocycline-susceptible Acinetobacter baumannii, but its …

Multidrug-resistant (MDR) Acinetobacter baumannii is increasingly more prevalent in
nosocomial infections. Although in vitro susceptibility of A. baumannii to minocycline is …

Acinetobacter baumannii is recognized as an urgent public health threat by the Centers for
Disease Control and Prevention (CDC). Current treatment options are scarce, particularly …

Among Acinetobacter species, A. baumannii and other closely related species are
commonly implicated in nosocomial infections. These organisms are usually multidrug …

Objectives The study investigated the effect of colistin and minocycline when tested singly
and in combination against Acinetobacter baumannii. Methods Thirteen unrelated imipenem …

Acinetobacter baumannii can cause life-threatening nosocomial infections associated with
high rates of morbidity and mortality. In recent years, the increasing number of infections due …

Carbapenem-resistant Acinetobacter baumannii is increasing in prevalence. Polymyxin B
and tigecycline are among the most active antibiotics used against this pathogen in vitro …

Minocycline is currently approved in the United States for the treatment of infections caused
by susceptible isolates of Acinetobacter spp. The objective of these studies was to determine …

The prevalence of heteroresistant Acinetobacter baumannii is increasing. Infections due to
these resistant pathogens pose a global treatment challenge. Here, the pharmacodynamic …